IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.821
AS - Asia 4.076
EU - Europa 2.178
SA - Sud America 575
Continente sconosciuto - Info sul continente non disponibili 509
AF - Africa 88
OC - Oceania 3
Totale 15.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.645
SG - Singapore 1.863
CN - Cina 761
IT - Italia 592
BR - Brasile 455
HK - Hong Kong 385
DE - Germania 369
VN - Vietnam 348
BD - Bangladesh 226
RU - Federazione Russa 197
UA - Ucraina 181
FR - Francia 170
IN - India 161
GB - Regno Unito 122
CA - Canada 93
FI - Finlandia 88
IE - Irlanda 84
SE - Svezia 69
TR - Turchia 54
KR - Corea 45
NL - Olanda 44
AR - Argentina 42
PL - Polonia 41
JP - Giappone 39
AT - Austria 37
BE - Belgio 34
MX - Messico 34
CZ - Repubblica Ceca 31
ES - Italia 31
IQ - Iraq 30
ZA - Sudafrica 30
CO - Colombia 21
ID - Indonesia 19
PK - Pakistan 17
CH - Svizzera 16
LT - Lituania 16
RO - Romania 16
EC - Ecuador 14
VE - Venezuela 14
SA - Arabia Saudita 13
IR - Iran 12
EG - Egitto 11
JM - Giamaica 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 8
CL - Cile 8
MA - Marocco 8
PY - Paraguay 8
DZ - Algeria 7
NP - Nepal 7
TH - Thailandia 7
BO - Bolivia 6
HN - Honduras 6
IL - Israele 6
PH - Filippine 6
TN - Tunisia 6
EE - Estonia 5
LB - Libano 5
LV - Lettonia 5
MY - Malesia 5
NI - Nicaragua 5
DK - Danimarca 4
JO - Giordania 4
KE - Kenya 4
KZ - Kazakistan 4
LA - Repubblica Popolare Democratica del Laos 4
NO - Norvegia 4
OM - Oman 4
PA - Panama 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TG - Togo 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
BS - Bahamas 3
CR - Costa Rica 3
EU - Europa 3
GR - Grecia 3
HU - Ungheria 3
PE - Perù 3
RS - Serbia 3
AU - Australia 2
BB - Barbados 2
BG - Bulgaria 2
BY - Bielorussia 2
BZ - Belize 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
GP - Guadalupe 2
KG - Kirghizistan 2
KH - Cambogia 2
MN - Mongolia 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
Totale 14.716
Salva come PNG Salva come JPEG
Città #
Ashburn 971
Singapore 873
Fairfield 717
San Jose 477
Chandler 446
Hong Kong 381
Council Bluffs 359
Woodbridge 346
Beijing 327
Seattle 306
Houston 281
Wilmington 243
Cambridge 227
Ann Arbor 207
Boardman 188
Los Angeles 169
Frankfurt am Main 156
New York 145
Lauterbourg 126
Dearborn 115
Jacksonville 100
Ho Chi Minh City 97
Dallas 93
Santa Clara 86
Dublin 79
Princeton 76
Buffalo 73
Munich 69
Hanoi 66
Dong Ket 64
The Dalles 57
Udine 54
Hefei 50
Phoenix 50
São Paulo 49
Milan 46
Redondo Beach 42
Seoul 42
San Diego 40
Rome 39
Washington 39
Chicago 38
Montreal 38
Warsaw 38
Tokyo 37
Orem 35
Helsinki 32
Brussels 29
Stockholm 28
Brooklyn 27
Izmir 27
Denver 26
London 26
Martignacco 26
Redmond 26
Brno 25
Des Moines 25
Ogden 25
Chennai 24
Nuremberg 22
Toronto 22
Turku 22
Johannesburg 20
Trieste 19
Belluno 18
Naples 18
Vienna 18
Shanghai 17
Atlanta 16
Boston 16
Guangzhou 16
Poplar 16
Amsterdam 15
Da Nang 15
Manchester 15
Mexico City 15
San Francisco 15
Zurich 15
Charlotte 14
Mumbai 14
Hyderabad 13
Lappeenranta 13
Newark 13
Ankara 12
Baghdad 12
Falls Church 12
Nanjing 12
Norwalk 12
Düsseldorf 11
Belo Horizonte 10
Changsha 10
City of London 10
Jinan 10
Leawood 10
New Delhi 10
Spinea 10
Arezzo 9
Augusta 9
Tashkent 9
Timisoara 9
Totale 9.477
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 230
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 225
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 202
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 197
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 197
Pattern of metastasis and outcome in patients with breast cancer 195
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 194
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 189
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 186
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 185
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 183
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 182
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 178
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 174
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 170
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 169
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 168
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 168
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 166
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 165
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 162
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 161
International expert consensus on the clinical integration of circulating tumor cells in solid tumors 160
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 158
Do platinum salts fit all triple negative breast cancers? 158
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 156
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 155
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 153
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 150
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 149
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 144
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 144
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 142
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 142
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 140
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 139
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 137
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 137
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 137
Determinants of Last-line Treatment in Metastatic Breast Cancer 135
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 135
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 135
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 134
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 133
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 133
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 131
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 129
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 129
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 128
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 128
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 127
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 127
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 125
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 125
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 124
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 122
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 120
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 115
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 114
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 114
Risk factors and survival outcomes in patients with brain metastases from breast cancer 113
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 112
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis 111
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 110
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 109
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology 107
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 107
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 107
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 105
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 104
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 101
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 101
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 99
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 97
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 95
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 94
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 94
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis 93
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 93
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 92
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 91
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity 90
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 90
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 87
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience 87
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis 87
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 86
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 86
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 85
null 84
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 84
Time to surgery after neoadjuvant chemotherapy for early breast cancer 83
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 81
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 78
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer 76
Landscape of circulating tumour DNA in metastatic breast cancer 76
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 75
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 75
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 75
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 74
Totale 12.904
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022596 0 0 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.566 130 158 97 107 186 119 175 145 315 172 413 549
2025/20266.060 576 516 382 562 867 573 658 214 419 443 536 314
2026/2027656 254 282 120 0 0 0 0 0 0 0 0 0
Totale 15.250